B-BRIDGE
DEAD

Serial Number

76664863

Owner

B-Bridge International, Inc.

Attorney

Maryam Imam

First Use Date

Nov 2, 2000

Filing Date

Aug 21, 2006

Add to watchlist:

No watchlists yet
View on USPTO

B-BRIDGE Trademark

Serial Number: 76664863 • Registration: 3486764

B-BRIDGE is a trademark filed by B-Bridge International, Inc. on August 21, 2006. The trademark is classified under Class 1 (Chemicals), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

B-Bridge International, Inc. (2 trademarks)

320 Logue Avenue
Mountain View, CA 94043

Entity Type: 03

Trademark Details

Filing Date

August 21, 2006

Registration Date

August 19, 2008

First Use Anywhere

November 2, 2000

First Use in Commerce

January 3, 2002

Published for Opposition

June 3, 2008

Cancellation Date

March 20, 2015

Goods & Services

Biosciences research products, namely, biochemical mechanisms used for research in the nature of transfection products, namely, quickstep transfection kit comprised of transfection reagents, for research purposes; Polymerase Chain Reaction (PCR) products, enzymes and reagents, namely, Taq deoxyribonucleic acid (DNA) Polymerase, Hot Start DNA Polymerase, deoxynucleotide triphosphate (dNTP) solutions, namely, sets of all four dNTPs 2'-Deoxyadenosine 5'-Triphosphate (dATP), 2'-Deoxycytidine 5'-Triphosphate (dCTP), 2'-Deoxyguanosine 5'-Triphosphate (dGTP), and 2'-Deoxythymidine 5'-Triphosphate (dTTP)), and Real Time PCR Kits comprised of chemicals, namely, DNA polymerase, Globin mixture containing glycerol, potassium chloride (KCl), dATP, dCTP, dGTP, dTTP and primers, magnesium chloride (MgCl2), reagents, and blood for research purposes; nucleic acid purification products, namely, plasmid DNA isolation kits comprised of chemicals, namely, transfection reagents for research purposes, ribonucleic acid (RNA) purification kits comprised of chemicals, namely, transfection reagents for research purposes, and high throughput purification kits comprised of chemicals, namely, buffers and buffers for lysis, binding, wash and elute, and mannitol-adenine-phosphate (MAP) solution containing mannitol, adenine and crystalline sodium dihydrogen phosphate for research purposes; apoptosis detection kits comprised of reagents for research purposes and chemicals consisting of buffers, fixatives, and biochemical stains; diabetes and obesity research products, namely, chemicals in the nature of human and mouse/rat adiponectin, resistin, leptin, and leptin-receptor enzyme-linked immunosorbent assay (ELISA) kits comprised of chemicals and anti-human leptin-receptor, wash buffer, recombinant human leptin-receptor, assay diluent, biotinylated anti-human leptin-receptor, concentrated horseradish peroxidase (HRP)-conjugated streptavidin, tetramethylbenzidine (TMB), and sulfuric acid substances for research purposes, and human endogenous secreted receptor for advanced glycation end products (esRAGE); ELISA kit comprised of chemicals in the nature of sulfuric acid, plate with absorbed anti-RAGE antibody, esRAGE intibody-horseradish peroxidase conjugated as Detection Antibody, 3,3', 5, 5'-tetramethylbenzidine and hydrogen peroxide, phosphate buffered saline containing bovine serum albumin, human esRAGE, phosphate buffered saline with Tween 20, for research purposes; interfering ribonucleic acid (RNAi) products, namely, small interfering RNA (siRNA) reagents for scientific research purpose, and GeneNet siRNA libraries and sequences in the nature of polymers for screening genome-wide for genes regulating cellular responses or signaling pathways, identifying potential drug targets or diagnostic markers that inhibit, enhance, or activate a selectable phenotype and finding crucial regulatory genes using routine growth selections or flow sorting; cell culture products, namely, chemicals in the nature of visceral adipocytes, epididymal adipocytes, subcutaneous adipocytes, and osteoclasts; chemicals for use in scientific research preparations, namely, full open reading frame (ORF) clones, full-length clones, sequence verified clones, and genomic clones for applications in protein expression, functional genomics, and functional analysis

Biological research, consulting, and analytical services, provided by scientists, in the nature of analysis of chemicals and biological sequences, sample analysis, ribonucleic acid (RNA) design in the nature of polymer design, small interfering ribonucleic acid (siRNA) design, siRNA synthesis in the nature of synthesis of polymers for scientific research, biological research of cells, cell strain, biochemical mechanisms, antibodies and proteins, apoptosis detection, cell culture, clones, food, and nucleic acid purification; providing of chemical laboratory facilities

Filing History

CANCELLED SEC. 8 (6-YR)
Mar 20, 2015 C8..
REGISTERED-PRINCIPAL REGISTER
Aug 19, 2008 R.PR
PUBLISHED FOR OPPOSITION
Jun 3, 2008 PUBO
NOTICE OF PUBLICATION
May 14, 2008 NPUB
LAW OFFICE PUBLICATION REVIEW COMPLETED
Apr 30, 2008 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 30, 2008 CNSA
EXAMINER'S AMENDMENT ENTERED
Apr 30, 2008 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Apr 30, 2008 GNEN
EXAMINERS AMENDMENT E-MAILED
Apr 30, 2008 GNEA
EXAMINERS AMENDMENT -WRITTEN
Apr 30, 2008 CNEA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Mar 14, 2008 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Mar 14, 2008 REAP
NON-FINAL ACTION MAILED
Feb 25, 2008 CNRT
NON-FINAL ACTION WRITTEN
Feb 22, 2008 CNRT
ASSIGNED TO EXAMINER
Jan 31, 2008 DOCK
WITHDRAWAL OF ATTORNEY GRANTED
Jan 16, 2008 WOAG
TEAS WITHDRAWAL OF ATTORNEY RECEIVED
Jan 16, 2008 WOAR
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Nov 1, 2007 ZZZX
WITHDRAWN FROM PUB - OG REVIEW QUERY
Oct 29, 2007 PBCR
LAW OFFICE PUBLICATION REVIEW COMPLETED
Oct 16, 2007 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 15, 2007 CNSA
EXAMINERS AMENDMENT MAILED
Oct 12, 2007 CNEA
EXAMINER'S AMENDMENT ENTERED
Oct 11, 2007 XAEC
EXAMINERS AMENDMENT -WRITTEN
Oct 11, 2007 CNEA
AMENDMENT FROM APPLICANT ENTERED
Sep 11, 2007 ACEC
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 11, 2007 CRFA
PAPER RECEIVED
Sep 7, 2007 MAIL
FINAL REFUSAL MAILED
Aug 27, 2007 CNFR
FINAL REFUSAL WRITTEN
Aug 27, 2007 CNFR
AMENDMENT FROM APPLICANT ENTERED
Aug 2, 2007 ACEC
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 2, 2007 CRFA
ASSIGNED TO LIE
Aug 2, 2007 ALIE
PAPER RECEIVED
Jul 19, 2007 MAIL
NON-FINAL ACTION MAILED
Apr 23, 2007 CNRT
NON-FINAL ACTION WRITTEN
Apr 22, 2007 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 27, 2007 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 26, 2007 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 26, 2007 TROA
COMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION ENTERED
Jan 29, 2007 CEPE
EXAMINER'S AMENDMENT/PRIORITY ACTION MAILED
Jan 26, 2007 CEAP
EXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED
Jan 26, 2007 CPEA
ASSIGNED TO EXAMINER
Jan 16, 2007 DOCK
APPLICATION FILING RECEIPT MAILED
Aug 29, 2006 MAFR
NEW APPLICATION ENTERED
Aug 25, 2006 NWAP